Therefore, the combination therapy involving D166 and anti-PD-1 represents a promising therapeutic approach for pancreatic cancer, where D166 functions as a STING agonist and serves as a sensitizer to anti-PD-1 therapy. Here, PDCD1 is linked to pancreatic neoplasm.